• 1. An autonomous self-optimizing flow machine for the synthesis of pyridine–oxazoline (PyOX) ligands?
  Eric Wimmer,Daniel Cortés-Borda,Solène Brochard,Elvina Barré,Charlotte Truchet,Fran?ois-Xavier Felpin React. Chem. Eng., 2019,4, 1608-1615
• 2. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli
• 3. An aqueous ammonia sensor based on an inkjet-printed polyaniline nanoparticle-modified electrode
  Karl Crowley,Eimer O'Malley,Aoife Morrin,Malcolm R. Smyth,Anthony J. Killard Analyst, 2008,133, 391-399
• 4. An analysis of the WTC fires using CIB correlations and simple modeling
  JGQuintiere
• 5. An amide probe as a selective Al3+ and Fe3+ sensor inside the HeLa and a549 cell lines: Pictet–Spengler reaction for the rapid detection of tryptophan amino acid?
  Bidyut Kumar Kundu,Rinky Singh,Ritudhwaj Tiwari,Debasis Nayak New J. Chem., 2019,43, 4867-4877

Introduction to 2,2,2-Trifluoro-1-(1H-Indazol-4-yl)ethan-1-one (CAS No. 2231676-70-1)

2,2,2-Trifluoro-1-(1H-indazol-4-yl)ethan-1-one, with the CAS number 2231676-70-1, is a synthetic compound that has garnered significant attention in the fields of medicinal chemistry and pharmaceutical research. This compound is characterized by its unique molecular structure, which includes a trifluoromethyl group and an indazole ring. These structural features contribute to its potential biological activities and make it a valuable candidate for various therapeutic applications.

The chemical formula of 2,2,2-trifluoro-1-(1H-indazol-4-yl)ethan-1-one is C₁₀H₆F₃N₃O, and its molecular weight is approximately 237.16 g/mol. The compound is a white crystalline solid at room temperature and is soluble in common organic solvents such as dimethyl sulfoxide (DMSO) and dimethylformamide (DMF). Its physical and chemical properties have been extensively studied to understand its behavior in different environments and its potential for pharmaceutical development.

In recent years, 2,2,2-trifluoro-1-(1H-indazol-4-yl)ethan-1-one has been the subject of numerous research studies due to its promising pharmacological properties. One of the key areas of interest is its potential as an inhibitor of specific enzymes involved in various disease pathways. For instance, studies have shown that this compound can effectively inhibit the activity of certain kinases, which are crucial enzymes in cell signaling pathways. This inhibition can lead to the modulation of cellular processes such as proliferation, apoptosis, and migration, making it a potential candidate for the treatment of cancers and other proliferative disorders.

Beyond its enzymatic inhibition properties, 2,2,2-trifluoro-1-(1H-indazol-4-yl)ethan-1-one has also been investigated for its anti-inflammatory effects. Inflammation is a complex biological response to harmful stimuli and is a key factor in many chronic diseases. Research has demonstrated that this compound can reduce the production of pro-inflammatory cytokines and chemokines, thereby mitigating inflammatory responses. This property makes it a promising candidate for the development of anti-inflammatory drugs.

The pharmacokinetic profile of 2,2,2-trifluoro-1-(1H-indazol-4-yl)ethan-1-one has also been studied to evaluate its suitability for therapeutic use. Preclinical studies have shown that it exhibits good oral bioavailability and a favorable distribution profile. Additionally, it has demonstrated low toxicity in animal models, which is a crucial factor for its potential use in human clinical trials. These findings suggest that 2,2,2-trifluoro-1-(1H-indazol-4-yl)ethan-1-one has a favorable safety profile and may be suitable for further development as a therapeutic agent.

In the context of drug discovery and development, the ability to synthesize compounds with specific structural features is crucial. The synthesis of 2,2,2-trifluoro-1-(1H-indazol-4-yl)ethan-1-one involves several steps that require precise control over reaction conditions to ensure high yields and purity. Recent advancements in synthetic chemistry have led to more efficient and scalable methods for producing this compound. These improvements have facilitated its availability for research purposes and have paved the way for further exploration of its biological activities.

Clinical trials are an essential step in the drug development process to assess the safety and efficacy of new compounds. While clinical trials involving 2,2,2-trifluoro-1-(1H-indazol-4-yl)ethan-1-one are still in their early stages, preliminary results are promising. Phase I trials have shown that the compound is well-tolerated by patients at various dose levels and has demonstrated preliminary evidence of therapeutic activity. These findings warrant further investigation in larger-scale clinical trials to fully evaluate its potential as a therapeutic agent.

In conclusion, 2,2,2-trifluoro-1-(1H-indazol-4-yl)ethan-1-one (CAS No. 2231676-70-1) is a promising compound with diverse biological activities that make it a valuable candidate for pharmaceutical research and development. Its unique molecular structure confers specific pharmacological properties that have been validated through extensive preclinical studies. Ongoing research continues to explore its potential applications in treating various diseases, particularly those involving inflammation and cancer. As more data from clinical trials become available, the therapeutic potential of this compound will become clearer.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)